Quantitative free light chain assays for the diagnosis and monitoring of monoclonal gammopathies

Journal of Clinical Ligand Assay

Volumn 27, Issue 4, 2004, Pages 246-255

  Katzmann, Jerry A ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Free light chains; Monoclonal gammopathies

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN M; PLASMA PROTEIN;

AMYLOIDOSIS; CELL PROLIFERATION; DIAGNOSTIC PROCEDURE; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; LIGHT CHAIN; LYMPHOPROLIFERATIVE DISEASE; MACROGLOBULINEMIA; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PLASMACYTOMA; PRACTICE GUIDELINE; PROTEIN ELECTROPHORESIS; QUANTITATIVE ANALYSIS; REVIEW;

EID: 20744433208     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Keren DF, Alexanian R, Goeken JA, et al.: Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123:106-107.
2. Kyle RA: Sequence of testing for monoclonal gammopathies-serum and urine assays. Arch Pathol Lab Med 1999;123:114-118.
3. Kyle RA, Gertz MA, Witzig TE, et al.: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21-23.
4. Solling K: Free light chains of immunoglobulins in normal serum and urine determined by radioimmunoassay. Scand J Clin Lab Invest 1975;35:407-412.
5. Solling K: Normal values of free light chains in serum in different age groups. Scand J Clin Lab Invest 1977;37:21-25.
6. Cole PW, Durie BGM, Salmon SE: Immunoquantitation of free light chain immunoglobulins: applications in multiple myeloma. J Immunol Methods 1978;19:341-349.
7. Robinson EL, Gowland E, Ward ID, Scarffe JH: Radioimmunoassay of free light chains of immunoglobulins in urine. Clin Chem 1982;28:2254-2258.
8. Brouwer J, Otting-van de Ruit M, Busking-van der Lely H: Estimation of free light chains of immunoglobulins by enzyme immunoassay. Clin Chim Acta 1985;150:257-274.
9. Hemmingsen L, Skaarup P: Urinary excretion of ten plasma proteins in patients with febrile diseases. Acta Med Scand 1977;201: 359-364.
10. Tillyer CR, Iqbal J, Raymond J, et al.: Immunoturbidometric assay for estimating free light chains of immunoglobulins in urine and serum. J Clin Pathol 1991;44:466-471.
11. Wakasugi K, Suzuki H, Imai A, et al.: Immunoglobulin free light chain assay using latex agglutination. Int J Clin Lab Res 1995;25: 211-215.
12. Ling NR, Lowe J, Hardie D, et al.: Detection of free κ chains in human serum and urine using pairs of monoclonal antibodies reacting with Cκ epitopes not available on whole immunoglobulins. Clin Exp Immunol 1983;52:234-240.
13. Axiak SM, Krishnamoorthy L, Guinan J, Raison RL: Quantitation of free κ light chains in serum and urine using a monoclonal antibody based inhibition enzyme-linked immunoassay. J Immunol Methods 1987;99:141-147.
14. Nelson M, Brown RD, Gibson J, Joshua DE: Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma. Br J Haematol 1992;81:223-230.
15. Abe M, Goto T, Kosaka M, et al.: Differences in kappa and lambda (κ:λ) ratios of serum and urinary free light chains. Clin Exp Immunol 1998;111:457-462.
16. Bradwell AR, Carr-Smith HD, Mead GP, et al.: Highly sensitive automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:637-680.
17. Katzmann JA, Clark RJ, Abraham RS, et al.: Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-1444.
18. Bradwell AR, Mead GP, Carr-Smith HD, Drayson MT: Serum test for assessment of patients with Bence Jones myeloma. Lancet 2003;361:489-491.
19. Abraham RS, Clark RJ, Bryant SC, et al.: Correlation of serum immunoglobulin free light chain quantitation with urine Bence Jones protein in light chain myeloma. Clin Chem 2002;48:655-657.
20. Alyanakian M, Abbas A, Delarue R, et al.: Free immunoglobulin light-chain serum levels in the follow-up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol 2004;75:246-248.
21. Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
22. Abraham RS, Katzmann JA, Clark RJ, et al.: Detection of serum immunoglobulin free light chains in primary systemic amyloidosis and light chain deposition disease by nephelometry. Clin Chem 2001;47(Suppl 6):A32 107.
23. Lachmann HJ, Gallimore R, Gillmore JD, et al.: Detection of monoclonal free light chains by nephelometry in systemic AL amyloidosis. Clin Chem 2002;48(Suppl 6):A164 E45.
24. Lachmann HJ, Gallimore R, Gillmore JD, et al: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78-84.
25. Abraham RS, Katzmann JA, Clark RJ, et al: Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-278.
26. Drayson MT, Tang LX, Drew R, et al.: Serum free light-chain measurements for identifying and monitoring patients with non-secretory multiple myeloma. Blood 2001;97:2900-2902.
27. Kyle RA, Therneau TM, Rajkumar VS, et al.: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569.
28. Rajkuman SV, Kyle RA, Therneau TM, et al: Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004;127:308-310.